GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2007

BioAlliance to Advance Immtech’s Pafuramidine in Europe for $3M Upfront

  • BioAlliance Pharma gained European commercialization rights to Immtech Pharmaceuticals’ pafuramidine maleate for $3 million. The compound is currently in Phase III trials for the treatment of pneumocystis pneumonia in AIDS patients and African sleeping sickness. Immtech also granted BioAlliance an option to commercialize pafuramidine in Europe for prevention and treatment of malaria in travelers.

    An additional $13 million will be paid as pafuramidine advances through European regulatory approval and pricing. BioAlliance will also make additional payments based on sales milestones and double-digit royalties.

    BioAlliance will contribute to clinical development funding of pafuramidine for malaria if the company exercises its option. Immtech will also obtain regulatory, pricing, and sales milestones and royalties related to the malaria program.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?